Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.
Tesaro's stock closed up 27.5% at $38.86 per share after the Waltham, Massachusetts-based company announced its advance into the cancer immunotherapy field
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
